Spots Global Cancer Trial Database for A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Official Title: A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
Study ID: NCT01416623
Conditions
Interventions
Study Description
Brief Summary: Henatinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study is designed to evaluate the safety and tolerability of Henatinib in patients with Advanced Solid Malignancies
Detailed Description: 1. To evaluate the safety and tolerability of Henatinib, and the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT). 2. To determine the pharmacokinetic profile of Henatinib and its metabolites . 3. To assess preliminary antitumor activity . 4. To determine preliminary regimen for phase II study .
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Name: jin Li, Dr
Affiliation: Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
